Project POINT: Effectiveness and Scalability of an Overdose Survivor Intervention
NCT03336268 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 249
Last updated 2023-10-06
Summary
The investigators seek to assess the effectiveness of Project POINT (Planned Outreach, Intervention, Naloxone, and Treatment). As originated in Indianapolis, Project POINT is a collaboration between Indianapolis Emergency Medical Services (EMS), the Eskenazi Emergency Department, Midtown Mental Health, and researchers at Indiana University. POINT is a quality improvement initiative that connects trained outreach workers with emergency department (ED) patients who experienced a non-fatal overdose. A member of the POINT team (a recovery coach or care coordinator with specialized training) meets patients after they have experienced an opioid overdose and, following a model of patient-centered care, offers them a range of evidence-based services including a brief assessment of high-risk behaviors, Hepatitis C and HIV testing, harm reduction counseling informed by motivational interviewing, and treatment referrals with follow-up to either a medication for opioid use disorder (MOUD) provider, detoxification services, or an inpatient treatment setting
The primary goal of this project is the establishment of POINT as an effective and scalable intervention for engaging patients in MAT. This study employs a Hybrid Type 1 effectiveness implementation design to take full advantage of current POINT expansion efforts currently happening in Indiana. The goal of this study is to replicate POINT in new hospitals and test its feasibility through (a) assessment of the chosen implementation strategy and (b) the testing of research protocols and secondary data collection procedures.
Conditions
Interventions
- BEHAVIORAL
-
POINT
A recovery coach meets patients in the ED after they have been revived from an overdose to offer a range of services including an assessment of high-risk behaviors, Hep C/HIV testing, harm reduction counseling, and treatment referrals with follow-up to either a medication for opioid use disorder (MOUD) provider, detoxification services, or an inpatient treatment setting. Patients are offered a take-home naloxone kit and assistance with Medicaid enrollment. Close collaboration with the local community mental health provider ensures POINT patients have their first assessment for MOUD within 1-2 business days of ED discharge. Also, recovery coaches offer to accompany patients to intake appointments or criminal justice and child welfare meetings as part of the standard care they deliver.
Sponsors & Collaborators
-
National Institute on Drug Abuse (NIDA)
collaborator NIH -
Indiana University
lead OTHER
Principal Investigators
-
Dennis P Watson, PhD · Indiana University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2018-02-12
- Primary Completion
- 2021-12-09
- Completion
- 2021-12-09
Countries
- United States
Study Locations
More Related Trials
-
Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone
NCT02294253 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder
NCT05011266 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Nasal Naloxone for Narcotic Overdose
NCT01912573 ·Status: UNKNOWN ·Phase: PHASE4
-
Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse
NCT01967641 ·Status: COMPLETED ·Phase: PHASE2
-
Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence
NCT00332228 ·Status: COMPLETED ·Phase: PHASE2
-
Overdose Risk Management and Naloxone
NCT03933345 ·Status: UNKNOWN
-
Buprenorphine Combination Tablet Feasibility - 1
NCT00000298 ·Status: COMPLETED ·Phase: PHASE2
-
Blockade Efficacy of Buprenorphine/Naloxone For Opioid Dependence
NCT00134888 ·Status: COMPLETED ·Phase: NA
-
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5
NCT00000330 ·Status: WITHDRAWN ·Phase: PHASE2
-
Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone
NCT00637000 ·Status: COMPLETED ·Phase: PHASE2
-
Surmounting Withdrawal to Initiate Fast Treatment With Naltrexone
NCT04762537 ·Status: COMPLETED ·Phase: NA
-
Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence
NCT03015246 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Developing and Testing the Opioid Rapid Response System
NCT04589676 ·Status: COMPLETED ·Phase: NA
-
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 - 4
NCT00000329 ·Status: WITHDRAWN ·Phase: PHASE2
-
Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1
NCT00032968 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Buprenorphine/Naloxone Continuation on Pain Control and Opioid Use
NCT03266445 ·Status: UNKNOWN ·Phase: PHASE4
-
Improving Availability of Intranasal Naloxone
NCT05877118 ·Status: RECRUITING ·Phase: NA
-
Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1
NCT00032955 ·Status: COMPLETED ·Phase: PHASE3
-
Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder
NCT02044094 ·Status: COMPLETED ·Phase: PHASE2
-
European Cohort Study of the Effectiveness of Take Home Naloxone
NCT05072249 ·Status: UNKNOWN
-
Prescription Opioid Addiction Treatment Study (POATS)
NCT00316277 ·Status: COMPLETED ·Phase: PHASE3
-
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1 - 1
NCT00000326 ·Status: WITHDRAWN ·Phase: PHASE2
-
Youth Opioid Recovery Support: A Developmentally-specific Intervention for Home Delivery of Extended Release Naltrexone
NCT03306368 ·Status: COMPLETED ·Phase: NA
-
SOONER Feasibility Study Protocol
NCT03821649 ·Status: COMPLETED ·Phase: NA
-
A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals
NCT01136356 ·Status: COMPLETED ·Phase: PHASE1/PHASE2